PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy

Area of Science:

• Urology
• Oncology
• Diagnostic Medicine

Background:

• The urinary PCA3 (prostate cancer gene 3) test is recognized for predicting repeat prostate biopsy outcomes.
• Recent advocacy suggests its use in predicting initial prostate biopsy results.

Purpose of the Study:

• To evaluate the performance of the PCA3 test in predicting initial prostate biopsy outcomes.
• To determine if incorporating the PCA3 test into existing nomograms enhances diagnostic value.

Main Methods:

• A prospective study of 601 patients undergoing initial prostate biopsy.
• PCA3 testing performed before a standard ≥12-core biopsy, alongside risk factor assessment.
• Evaluation of three nomograms (Hansen's, Chun's, PCPT) with PCA3 incorporation for predicting any prostate cancer (PCa) and high-grade prostate cancer (HGPCa).

Main Results:

• The PCA3 score demonstrated significant predictive accuracy for initial biopsy outcomes.
• Chun's and Hansen's nomograms showed good calibration and high net benefit.
• Using nomogram-derived thresholds (≤30% PCa probability) could avoid up to 48% of unnecessary biopsies, missing only ≤6% of HGPCa.

Conclusions:

• The urinary PCA3 test is a reliable tool for aiding initial prostate biopsy decisions.
• PCA3-incorporating nomograms improve diagnostic accuracy and reduce unnecessary procedures.
• These tools support informed decisions regarding initial prostate biopsies.